Ferozsons Laboratories

Ferozsons Laboratories, established in 1956, stands as a significant player within the Pharmaceuticals and Healthcare industries. The company has cultivated a profound commitment to advancing public health, particularly through its decade-long dedication to the critical mission of hepatitis elimination throughout Pakistan. This extensive experience has enabled them to deliver world-class treatments, directly benefiting thousands of patients and establishing a strong foundation for their ongoing health initiatives.

The operational scale of Ferozsons Laboratories is supported by a dedicated team of 500 - 1,000 employees, managing a network of 3 distinct locations. Their product offerings encompass a range of generic, pharmaceutical, and molecule-based solutions, actively traded on the stock exchange under the ticker PSX: FEROZ. For detailed insights into the company's leadership and the professionals driving its strategic objectives, interested parties can Meet Ferozsons Laboratories' team.

A cornerstone of Ferozsons Laboratories' current strategy involves a new, community-focused project designed to forge vital partnerships. This initiative is geared towards ensuring appropriate screening, comprehensive prevention strategies, and effective treatment for Hepatitis C patients. By implementing localized interventions and robust care pathways, the company actively addresses pressing health challenges, solidifying its position as a pivotal contributor to Pakistan's evolving healthcare ecosystem and its fight against viral hepatitis.